EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

(2011) B. P. Pollack et al.   CLINICAL CANCER RESEARCH

Strategies to counteract MHC-I defects in tumors

(2011) Margit H Lampen et al.   CURRENT OPINION IN IMMUNOLOGY

Strength of TCR-Peptide/MHC Interactions and In Vivo T Cell Responses

(2011) E. Corse et al.   JOURNAL OF IMMUNOLOGY

Interferon-γ links ultraviolet radiation to melanomagenesis in mice

(2011) M. Raza Zaidi et al.   NATURE

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

(2011) Joachim Lupberger et al.   NATURE MEDICINE

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacological inhibition of EGFR signaling enhances G-CSF–induced hematopoietic stem cell mobilization

(2010) Marnie A Ryan et al.   NATURE MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR Signaling and Drug Discovery

(2010) Georg Lurje et al.   ONCOLOGY

Epitope Density Influences CD8+ Memory T Cell Differentiation

(2010) Julie Leignadier et al.   PLoS One

Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells

(2009) M. Lotem et al.   CLINICAL CANCER RESEARCH

Ultraviolet B Radiation Generated Platelet-Activating Factor Receptor Agonist Formation Involves EGF-R-Mediated Reactive Oxygen Species

(2009) Y. Yao et al.   JOURNAL OF IMMUNOLOGY

Should we be surprised at the paucity of response to EGFR inhibitors?

(2009) Barry A Gusterson et al.   LANCET ONCOLOGY

The Koebner-Phenomenon in Epidermal Growth Factor Receptor Inhibitor–Induced Cutaneous Adverse Effects

(2008) Peter Arne Gerber et al.   JOURNAL OF CLINICAL ONCOLOGY